BioCentury
ARTICLE | Emerging Company Profile

Ex-Mavupharma execs reunite at Inipharm to build liver disease pipeline

Emerging Company Profile: Inipharm will use its $35M series A to advance lead liver program through Phase I

November 14, 2020 4:08 AM GMT
Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article